Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?

Barbara Alicja Jereczek-Fossa, Sara Ronchi, Roberto Orecchia, Barbara Alicja Jereczek-Fossa, Sara Ronchi, Roberto Orecchia

Abstract

Objectives: To review the available data about stereotactic body-radiotherapy (SBRT) for oligometastatic lymph node cancer recurrence.

Methods: The inclusion criteria for this study were as follows: Medline search for the (1) English language (2) full paper (abstracts were excluded) on (3) adult oligometastatic solid cancer recurrence limited to lymph node that underwent SBRT (4) outcome data available and (5) published up to the 30th April 2014.

Results: 38 papers fulfilling the inclusion criteria have been found: 7 review articles and 31 patient series (20 and 11 retrospective and prospective studies, respectively) including between 1 and 69 patients (636 lymph nodes). Twelve articles reported only lymph node SBRT while in 19 - all types of SBRT including lymph node SBRT were presented. Two-year local control, 4-year progression free survival and overall survival was of up to 100%, 30% and 50%, respectively. The progression was mainly out-field (10-30% of patients had a recurrence in another lymph node/nodes). The toxicity was low with mainly mild acute events and single grade 3-4 late events. When compared to SBRT for any oligometastatic cancer, SBRT for lymph node recurrence carried better prognosis and showed lower toxicity.

Conclusions: SBRT is a feasible approach for oligometastatic lymph node recurrence, offering excellent in-field tumor control with low toxicity profile. The potential abscopal effect has been hypothesized as a basis of these findings. Future studies are warranted to identify the patients that benefit most from this treatment. The optimal combination with systemic treatment should also be defined.

Keywords: Lymph nodes; Oligometastatic cancer; Recurrent cancer; Stereotactic body radiotherapy.

References

    1. Hellman S., Weichselbaum R.R. Oligometastases. J. Clin. Oncol. 1995;13:8–10.
    1. Weichselbaum R.R., Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–382.
    1. Ripley R.T., Downey R.J. Pulmonary metastasectomy. J. Surg. Oncol. 2014;109:42–46.
    1. Ruiterkamp J., Ernst M.F. The role of surgery in metastatic breast cancer. Eur. J. Cancer. 2011;47(Suppl. 3):S6–S22.
    1. Tree A.C., Khoo V.S., Eeles R.A. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14:e28–e37.
    1. De Meerleer G., Khoo V., Escudier B. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15:e170–e177.
    1. Takeda A., Sanuki N., Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J. Gastroenterol. 2014;20:4220–4229.
    1. Seo Y.S., Kim M.S., Yoo H.J., Jang W.I. Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer. World J. Gastroenterol. 2014;20:2005–2013.
    1. Alongi F., Arcangeli S., Filippi A.R., Ricardi U., Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17:1100–1107.
    1. Almaghrabi M.Y., Supiot S., Paris F., Mahé M.A., Rio E. Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. Radiat Oncol. 2012;7:126.
    1. De Bari B., Alongi F., Buglione M. Salvage therapy of small volume prostate cancer nodal failures: a review of the literature. Crit. Rev. Oncol. Hematol. 2014;90:24–35.
    1. Di Muzio N., Fodor A., Berardi G. Lymph nodal metastases: diagnosis and treatment. Q J Nucl Med Mol Imaging. 2012;56:421–429.
    1. Kang J.K., Kim M.S., Kim J.H. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin. Exp. Metastasis. 2010;27:273–278.
    1. Bae S.H., Kim M.S., Cho C.K. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J. Surg. Oncol. 2012;106:138–143.
    1. Jereczek-Fossa B.A., Beltramo G., Fariselli L. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012;82:889–897.
    1. Jereczek-Fossa B.A., Bossi-Zanetti I., Mauro R. CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer: a prospective evaluation of 95 patients/118 lesions. Strahlenther. Onkol. 2013;189:448–455.
    1. Berkovic P., De Meerleer G., Delrue L. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27–32.
    1. Ahmed K.A., Barney B.M., Davis B.J., Park S.S., Kwon E.D., Olivier K.R. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2013;2:215.
    1. Hoyer M., Roed H., Traberg Hansen A. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–830.
    1. Kodani N., Yamazaki H., Tsubokura T. Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. J Radiat Res. 2011;52:24–31.
    1. Roh K.W., Jang J.S., Kim M.S. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:1348–1355.
    1. Greco C., Zelefsky M.J., Lovelock M. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int. J. Radiat. Oncol. Biol. Phys. 2011;79:1151–1157.
    1. Wersäll P.J., Blomgren H., Lax I. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 2005;77:88–95.
    1. Salama J.K., Hasselle M.D., Chmura S.J. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118:2962–2970.
    1. Kawaguchi K., Sato K., Horie A. Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma. Radiat Oncol. 2010;5:51.
    1. Scorsetti M., Alongi F., Castiglioni S. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol. 2011;6:113.
    1. Scorsetti M., Bignardi M., Alongi F. Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: feasibility and clinical preliminary results. Acta Oncol. 2011;50:528–538.
    1. Milano M.T., Katz A.W., Muhs A.G. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112:650–658.
    1. Milano M.T., Katz A.W., Schell M.C., Philip A., Okunieff P. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2008;72:1516–1522.
    1. Milano M.T., Philip A., Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int. J. Radiat. Oncol. Biol. Phys. 2009;73:832–837.
    1. Milano M.T., Katz A.W., Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am. J. Clin. Oncol. 2010;33:157–163.
    1. Bonomo P., Cipressi S., Saieva C. Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases. Tumori. 2013;99:611–616.
    1. Alongi F., Fogliata A., Clerici E. Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol. 2012;7:204.
    1. Corvò R., Lamanna G., Vagge S. Once-weekly stereotactic radiotherapy for patients with oligometastases: compliance and preliminary efficacy. Tumori. 2013;99:159–163.
    1. Jereczek-Fossa B.A., Piperno G., Ronchi S. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am. J. Clin. Oncol. 2012 [Epub ahead of print]
    1. Bignardi M., Navarria P., Mancosu P. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int. J. Radiat. Oncol. Biol. Phys. 2011;81:831–838.
    1. Casamassima F., Masi L., Menichelli C. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49–55.
    1. Jereczek-Fossa B.A., Fariselli L., Beltramo G. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother. Oncol. 2009;93:14–17.
    1. Kim J.H., Kim M.S., Yoo S.Y., Lim S.M., Lee G.H., Yi K.H. Stereotactic body radiotherapy for refractory cervical lymph node recurrence of nonanaplastic thyroid cancer. Otolaryngol. Head Neck Surg. 2010;142:338–343.
    1. Kim M.S., Yoo S.Y., Cho C.K. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J. Korean Med. Sci. 2009;24:488–492.
    1. Choi C.W., Cho C.K., Yoo S.Y. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:147–153.
    1. Kim M.S., Cho C.K., Yang K.M., Lee D.H., Moon S.M., Shin Y.J. Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J. Gastroenterol. 2009;15:6091–6095.
    1. Kim M.S., Choi C., Yoo S. Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. Jpn. J. Clin. Oncol. 2008;38:695–700.
    1. Malicki J. The importance of accurate treatment planning, delivery, and dose verification. Rep Pract Oncol Radiother. 2012;17:63–65.
    1. Nithiyananthan K., Mani G.K., Subramani V., Palaniappan K.K., Uthiran M., Vellengiri S. Influence of segment width on plan quality for volumetric modulated arc based stereotactic body radiotherapy. Rep Pract Oncol Radiother. 2014;19(5) (in press)
    1. Rubio C., Morera R., Hernando O., Leroy T., Lartigau E. Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors. Rep Pract Oncol Radiother. 2013;18:387–396.
    1. Chua T.C., Liauw W., Chu F., Morris D.L. Viewing metastatic colorectal cancer as a curable chronic disease. Am. J. Clin. Oncol. 2012;35:77–80.
    1. Grimaldi A.M., Simeone E., Giannarelli D., Muto P., Falivene S., Borzillo V. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780.
    1. Scheithauer H., Belka C., Lauber K., Gaipl U.S. Immunological aspects of radiotherapy. Radiat Oncol. 2014;9:185. [Epub ahead of print]
    1. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365–372.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다